WANY
PTCT icon

Wealthspire Advisors (New York)’s PTC Therapeutics PTCT Stock Holding History

Wealthspire Advisors (New York)’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14
Closed -$859 – 2415
2025
Q3 		$859 Buy
+14
New +$729 ﹤0.01% 2764

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wealthspire Advisors (New York)'s PTCT Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of PTC Therapeutics (PTCT) in Q4 2025, closing a stake of 14 shares — an estimated $859 sold.

Wealthspire Advisors (New York) first reported a position in PTCT in Q3 2025 and held it in 1 quarter. The position peaked at $859 in Q3 2025. 353 funds tracked by Wall St. Rank hold PTCT as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining PTC Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 14 PTC Therapeutics shares in Q4 2025, an estimated $859.
  • Wealthspire Advisors (New York) first reported a position in PTC Therapeutics in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s PTC Therapeutics position peaked at $859 in Q3 2025.
  • 353 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.